AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes 2024 as the base year in the compound annual growth rate calculation. AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues. The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $27B, an increase of approximately $6B compared to previous guidance for combined revenues of more than $21B in 2027. AbbVie is also raising its long-term outlook for Ubrelvy and Qulipta revenues. The company now expects peak combined Ubrelvy and Qulipta revenues of more than $3B, an increase of approximately $1B compared to previous guidance for peak revenues of more than $1B for each asset.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- ABBV Earnings this Week: How Will it Perform?
- Palo Alto downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls